TG Ther­a­peu­tics maps a short­cut to the FDA with lead drug for CLL

TG Ther­a­peu­tics $TGTX will take a shot at short­en­ing the Phase III run­way for its lead ef­fort on ubli­tux­imab (TG-1101).

The biotech, which has been grap­pling with en­roll­ment is­sues, says it plans to lop off the sec­ond stage of what was once a two-step de­vel­op­ment ap­proach, drop­ping a look at pro­gres­sion-free sur­vival with the FDA’s bless­ing and hus­tling over­all re­sponse rate da­ta to reg­u­la­tors if it bags pos­i­tive re­sults in the first half of 2017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER